Detrol LA Doctor’s office TV commercial
Click here to view all Detrol LA ads on AdPharm.net
Tolterodine acts on M2 and M3 subtypes of muscarinic receptors whereas most antimuscarinic treatments for overactive bladder only act on M3 receptors making them more selective. It is marketed and distributed by Pfizer inc.
Tolterodine, although it acts on two types of receptors, has fewer side effects than other antimuscarinics eg. oxybutynin (which is selective for M3 only) as tolterodine targets the bladder more than other areas of the body. This means that less drug needs to be given daily (due to efficient targeting of the bladder) and so there are fewer side effects.
Leave a Reply
You must be logged in to post a comment.
